Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nezar Dahdal

Internal Medicine Glendale, AZ Medical Doctor

NPI 1194977405 CMS profile 824298

5421 W Thunderbird Rd, Glendale, AZ 85306

Open in the dashboard

General payments

$3,215

171 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nezar Dahdal of Glendale, AZ is reported in the CMS Open Payments database as having received $3,215 across 171 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $741 47
2024 General $730 27
2023 General $849 57
2022 General $819 38
2021 General $76 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nezar Dahdal
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Nezar Dahdal were reported at $741. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Nezar Dahdal Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $76 $135 $37–$521 $132
2022 $819 $141 $42–$496 $149
2023 $849 $149 $45–$519 $160
2024 $730 $154 $47–$537 $164
2025 $741 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $463 26 payments
  2. AstraZeneca Pharmaceuticals LP $437 12 payments
  3. Lilly USA, LLC $390 26 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $338 5 payments
  5. AbbVie, Inc. $276 22 payments
  6. Amgen Inc. $225 20 payments
  7. Edwards Lifesciences Corporation $181 3 payments
  8. Nestle HealthCare Nutrition Inc. $144 10 payments
  9. Abbott Laboratories $144 7 payments
  10. Aimmune Therapeutics, Inc. $139 15 payments
  11. Other $479 25 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,215 171 payments
Products named General payments · program years 2021–2025
  1. AIRSUPRA $380 8 payments
  2. LifeVest $338 5 payments
  3. BREZTRI $335 5 payments
  4. FARXIGA $308 3 payments
  5. ZENPEP $283 25 payments
  6. Ozempic $274 11 payments
  7. Otezla $225 20 payments
  8. MOUNJARO $221 14 payments
  9. JARDIANCE $169 12 payments
  10. RYBELSUS $166 10 payments
  11. Other $1,714 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 66 drugs

Part D claims

2,429

Median for Hospitalist: 109

Drug cost

$220,539

Median for Hospitalist: $6,399

Branded share of claims

18.4%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 57 $71,058
Trulicity Dulaglutide Brand 23 $27,043
Jardiance Empagliflozin Brand 23 $25,832
Januvia Sitagliptin Phosphate Brand 21 $21,384
Ozempic Semaglutide Brand 12 $15,178
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 12 $13,664
Creon Lipase/Protease/Amylase Brand 15 $10,032
Rosuvastatin Calcium Generic 138 $3,417
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 31 $2,800
Levemir Insulin Detemir Brand 13 $2,082

The 10 drugs with the highest cost, of 66 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$47,899

Medicare's payments for the services billed

Medicare patients

218

Average age 74

Services billed

999

116 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Chronic kidney disease 40%
Diabetes 35%
Ischemic heart disease 33%
Heart failure 26%
COPD 25%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $151
$151 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $86
$86 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $72
$72 12 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $58
$58 57 —
JARDIANCE
  • Lilly USA, LLC $30
$30 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

171 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record